Despite significant advancements in HIV treatment allowing for longer and healthier lives, a critical and preventable threat remains: tobacco use. New research underscores that smoking is a leading cause of illness and death among people living with HIV, and poses a risk comparable too – or exceeding – the impact of the virus itself.This report examines the disproportionately high rates of smoking within the HIV community, the complex interplay between tobacco and the disease, and the growing recognition of nicotine cessation as an essential component of thorough HIV care.
For people living with HIV, smoking remains a leading preventable cause of illness and death. Despite significant advances in antiretroviral treatments, tobacco use continues to negatively impact health, lifespan, and quality of life. Quitting smoking is a crucial step in reducing complications and improving the overall effectiveness of HIV care. This is particularly important as people with HIV are living longer, healthier lives thanks to modern medicine, making preventable conditions like those caused by smoking even more impactful.
Smoking Prevalence is Significantly Higher Among People with HIV
Tobacco use is significantly more common among individuals living with HIV compared to the general population. Data indicates a prevalence that is two to three times higher, reflecting an increased vulnerability to nicotine addiction. This disparity is due to a combination of factors, including social determinants of health, the psychosocial burden of diagnosis, and a higher frequency of co-occurring health conditions.
Prolonged exposure to tobacco smoke has major health consequences. People with HIV who smoke have an increased risk of cardiovascular diseases, tobacco-related cancers, chronic respiratory illnesses, and pulmonary infections. In settings where access to antiretroviral treatments is optimal, smoking now stands as one of the primary factors limiting gains in life expectancy, potentially having an impact equal to, or even greater than, that of HIV itself.
Negative Interactions with the Immune System and Treatments
Smoking has well-documented detrimental effects on the immune system, which are particularly relevant for people living with HIV. It is associated with increased chronic inflammation and impaired immune defense mechanisms, especially at the cellular level. These disruptions can increase vulnerability to opportunistic infections and contribute to a faster decline in overall health.
These effects occur in the context of HIV infection, which directly targets key cells within the immune system. Smoking exacerbates persistent inflammatory processes, now recognized as an important driver of non-AIDS-related comorbidities, such as cardiovascular disease, certain cancers, and chronic lung diseases. This low-grade inflammation, fueled by tobacco use, can limit the long-term benefits of antiretroviral treatments, even when viral load is controlled.
Furthermore, tobacco use is linked to challenges with adherence to medical care. People living with HIV who smoke are more likely to experience problems with medication adherence and less frequent engagement with medical follow-up. These factors can jeopardize the maintenance of an undetectable viral load and compromise the overall effectiveness of long-term care. [1] These challenges highlight the need for integrated care approaches that address both HIV and tobacco dependence.
Nicotine Cessation: A Central Component of Comprehensive HIV Care
Quitting smoking is a major determinant of improved health for people living with HIV. The benefits are both rapid and lasting, impacting multiple dimensions of health. Physiologically, quitting leads to improved respiratory function and a progressive reduction in cardiovascular risk, which is particularly elevated in this population. Positive effects on immune balance have also been reported, contributing to a better overall state of health.
In the medium to long term, quitting smoking significantly reduces the incidence of tobacco-related cancers, chronic lung diseases, and cardiovascular events, which now account for a substantial portion of morbidity and mortality among people living with HIV. These benefits are accompanied by an improved quality of life, with reductions in shortness of breath, fatigue, and certain mental health issues associated with nicotine dependence.
In this context, nicotine cessation is a cornerstone of comprehensive HIV care, as important as viral and immunological monitoring. Health authorities recommend the systematic integration of smoking cessation support into care pathways, based on an approach combining behavioral support and validated cessation aids. [2] Such integration strengthens the effectiveness of antiretroviral treatments, secures long-term follow-up, and optimizes the benefits of therapeutic advances.
Beyond the individual clinical impact, quitting smoking among people living with HIV is a matter of broader public health and reducing health inequities. By addressing a preventable risk factor, it is possible to sustainably improve life expectancy and quality of life, while strengthening the coherence of HIV prevention and care policies.
AE
[1] How Does Smoking Affect People with HIV?, HIV.gov, updated September 18, 2025
[2] How quitting nicotine can benefit people living with HIV, Truth Initiative, published December 15, 2025, accessed the same day
